{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:57:38Z","timestamp":1791352658710,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.critrevonc.2013.08.016","type":"journal-article","created":{"date-parts":[[2013,9,8]],"date-time":"2013-09-08T01:16:15Z","timestamp":1378602975000},"page":"248-261","source":"Crossref","is-referenced-by-count":28,"title":["Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"89","author":[{"given":"Maria","family":"Gkotzamanidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos A.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"No authors listed","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic largecell lymphoma): results from the non-Hodgkin's lymphoma classification project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0025","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.08.016_bib0030","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1997.15.6.2296","article-title":"Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma","volume":"15","author":"Ansell","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.016_bib0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","article-title":"The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas","volume":"129","author":"Sonnen","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.08.016_bib0040","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2013.08.016_bib0045","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.critrevonc.2013.08.016_bib0050","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.08.016_bib0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodriguez","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.016_bib0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/path.945","article-title":"p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome","volume":"195","author":"Pescarmona","year":"2001","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.1346","article-title":"BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.08.016_bib0070","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0075","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.08.016_bib0080","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.08.016_bib0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0100","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.critrevonc.2013.08.016_bib0105","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"D\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.08.016_bib0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0125","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5507\/bp.2011.009","article-title":"Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation","volume":"155","author":"Prochazka","year":"2011","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2013.08.016_bib0140","first-page":"6565","article-title":"Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for non cutaneous T-cell lymphoma (TCL): the university of Texas M.D. Anderson cancer center (MDACC) experience","volume":"29","author":"Beitinjaneh","year":"2011","journal-title":"ASCO Meeting Abstr"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.08.016_bib0145","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3109\/10428194.2011.569038","article-title":"Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer\/T-cell lymphoma","volume":"52","author":"Hwang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0150","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-013-1685-5","article-title":"Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial","author":"Ahn","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.critrevonc.2013.08.016_bib0160","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.critrevonc.2013.08.016_bib0165","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V76.2.424.424","article-title":"Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas","volume":"76","author":"Vose","year":"1990","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.08.016_bib0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1701596","article-title":"Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Fanin","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.critrevonc.2013.08.016_bib0180","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.08.016_bib0185","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.08.016_bib0190","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0195","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0200","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.08.016_bib0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","article-title":"High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma","volume":"33","author":"Zamkoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0215","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.08.016_bib0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.016_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.08.016_bib0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0240","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"Yang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.96.96","article-title":"Survival of peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors","volume":"118","author":"Mak","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.08.016_bib0255","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","article-title":"High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors","volume":"17","author":"Nademanee","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0260","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-013-1716-2","article-title":"Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis","author":"Czyz","year":"2013","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0265","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0270","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0275","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2008.01.002","article-title":"Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.critrevonc.2013.08.016_bib0280","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.critrevonc.2013.08.016_bib0285","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.016_bib0290","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0295","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.08.016_bib0300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O\u2019Connor","year":"2007","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.08.016_bib0305","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0310","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.08.016_bib0315","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.critrevonc.2013.08.016_bib0320","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.08.016_bib0330","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.08.016_bib0335","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.critrevonc.2013.08.016_bib0340","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.08.016_bib0345","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0350","series-title":"Romidepsin: Sponsor's background package for the Oncologic Drugs Advisory Committee Meeting, September 2","author":"Gloucester Pharmaceuticals Inc.","year":"2009"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.08.016_bib0355","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","article-title":"Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma","volume":"30","author":"Dong","year":"2013","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0365","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.5000.5000","article-title":"Alemtuzumab in combination with interferon-\u03b1 or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results","volume":"112","author":"Rupoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0375","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2005.2005","article-title":"Phase I results of combination gemcitabine and bortezomib (Velcade\u00ae) for relapsed\/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL)","volume":"112","author":"Evens","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2466.2466","article-title":"Cutaneous T cell lymphoma: responses in phase 1 trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine","volume":"108","author":"Dhillon","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0385","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.08.016_bib0390","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.08.016_bib0395","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.08.016_bib0400","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.08.016_bib0405","first-page":"961","article-title":"Complete remissions with Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"116","author":"Shustov","year":"2010","journal-title":"ASH Ann Meeting Abstr"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0410","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.283.283","article-title":"Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2013.08.016_bib0415","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0420","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.08.016_bib0425","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdn726","article-title":"Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study","volume":"20","author":"Kim","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.08.016_bib0430","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity","volume":"30","author":"Kim","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2013.08.016_bib0435","unstructured":"Clinical trials.gov. [website] [Accessed 03.03.13]."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:04:30Z","timestamp":1596456270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1040842813001935"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}